24/7 Market News Snapshot 06 September, 2024 – Travere Therapeutics, Inc. Common Stock (NASDAQ:TVTX)

September 6, 2024

DENVER, Colo., 06 September, 2024 (247marketnews.com) – (Nasdaq:TVTX) are discussed in this article.
Travere Therapeutics, Inc. (Nasdaq:TVTX) has garnered notable investor attention as its stock opened at $10.80, reflecting a significant uptick of 10.16% from the prior session’s close of $9.93, and is currently trading at $10.94. This positive trend is accompanied by a robust trading volume of 3.90 million shares, signaling strong market interest. The breakout suggests that the stock is not only surpassing critical resistance levels but is also displaying favorable technical indicators, which hint at an optimistic outlook in the short term. Investors should monitor the support level at $10.80, with further growth potentially targeting $11.50.

In conjunction with this market momentum, Ligand Pharmaceuticals Incorporated (Nasdaq:LGND) has celebrated the FDA’s full approval of FILSPARI® (sparsentan), a groundbreaking treatment for primary IgA nephropathy (IgAN), which slows the progression of kidney disease in adults. This milestone comes shortly after the accelerated approval, based on initial results demonstrating the medication’s efficacy in reducing proteinuria — a crucial marker for kidney health. The PROTECT Study further verified FILSPARI’s ability to significantly slow the decline in kidney function over two years compared to existing therapies.

Todd Davis, Ligand’s CEO, conveyed enthusiasm for this landmark development stating, “This announcement marks a pivotal moment for Travere and offers renewed hope for individuals affected by this rare kidney disease.” Notably, FILSPARI is distinguished as the only oral, once-daily, non-immunosuppressive treatment specifically targeting IgAN-induced glomerular injury, showcasing a well-tolerated safety profile across clinical trials. Ligand’s ongoing partnership with Travere positions it to benefit from future milestone payments and royalties as both companies strive to enhance patient outcomes in this therapeutic landscape.

Related news for (TVTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.